Monte Rosa Therapeutics
GLUE
53 hedge funds and large institutions have $561M invested in Monte Rosa Therapeutics in 2022 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 25 increasing their positions, 7 reducing their positions, and 11 closing their positions.
257% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 7
7.89% more ownership
Funds ownership: 78.13% → 86.03% (+7.9%)
0% more funds holding
Funds holding: 53 → 53 (0)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 11
24% less capital invested
Capital invested by funds: $742M → $561M (-$181M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$26.7M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$16.7M |
| 3 |
BlackRock
New York
|
+$10.8M |
| 4 |
State Street
Boston,
Massachusetts
|
+$2.36M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$10.8M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$6.13M |
| 3 |
OCA
Octagon Capital Advisors
New York
|
-$3.06M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
-$1.95M |
| 5 |
E
Ergoteles
New York
|
-$1.52M |
GLUE Hedge Fund Activity: Q1 2022 in Review
53 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Monte Rosa Therapeutics (GLUE) for Q1 2022, worth a combined $561M — down 24% from $742M a quarter earlier.
Fund positioning in GLUE was balanced in Q1 2022: 11 funds opened new positions, 11 closed out, 25 added to existing stakes and 7 trimmed.
The largest buyer was Vanguard Group, adding an estimated $26.7M. The largest seller was Jennison Associates, exiting entirely with an estimated $10.8M sold.
- 53 institutional investors held Monte Rosa Therapeutics (GLUE) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $561M of Monte Rosa Therapeutics stock for Q1 2022, down 24% quarter-over-quarter.
- 11 funds opened new Monte Rosa Therapeutics positions in Q1 2022 and 11 closed out, a net change of 0 holders.
- The largest Monte Rosa Therapeutics buyer in Q1 2022 was Vanguard Group, an estimated $26.7M added.
- The largest Monte Rosa Therapeutics seller in Q1 2022 was Jennison Associates, an estimated $10.8M sold.
Based on aggregated 13F filings for Q1 2022.